Nivolumab (Nivo) plus Ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced Non-Small-Cell-Lung Cancer (aNSCLC): results of the randomized IFCT-1701 phase 3 trial

Etude concernée: IFCT-1701
Auteurs / Authors: Zalcman G.
Journal / Conference: ESMO
Année / Year: 2022
PMID: Oral session
Lien vers la publication: https://oncologypro.esmo.org/meeting-resources/esmo-congress/nivolumab-nivo-plus-ipilimumab-ipi-6-months-treatment-versus-continuation-in-patients-with-advanced-non-small-cell-lung-cancer-ansclc-result